Last updated: February 21, 2026
What is NDC 44087-1150?
NDC 44087-1150 corresponds to Repatha (evolocumab), a monoclonal antibody used to lower LDL cholesterol. It was approved by the FDA in 2015. Repatha is marketed by Amgen and primarily prescribed for hyperlipidemia and familial hypercholesterolemia.
Market Size and Growth Drivers
Market Overview
The global PCSK9 inhibitor market, which includes evolocumab, projected to reach approximately $10 billion by 2025[1]. The key drivers are:
- Increasing prevalence of cardiovascular disease.
- Growing awareness of LDL cholesterol management.
- Expanding insurance coverage and reimbursement.
Market Segments
- Cardiovascular patients not achieving LDL goals with statins.
- Familial hypercholesterolemia cases.
- Prevention in high-risk populations.
Key Competitors
- Alirocumab (Praluent, Regeneron/Sanofi).
- Inclisiran (Leqvio, Novartis).
Market Share (2022)
| Product |
Market Share |
| Repatha (Evolocumab) |
~55% |
| Praluent (Alirocumab) |
~35% |
| Inclisiran |
~10% |
Pricing and Reimbursement Landscape
Current Pricing
- List price for Repatha: approximately $5,850 per year per patient (based on monthly injections).
- Discounted prices with insurance or pharmacy benefit managers (PBMs): estimated effective cost $3,500–$4,200 annually[2].
Reimbursement Trends
- Reimbursement remains favorable in commercial plans; coverage exceeds 85%.
- Many payers require prior authorization and proof of statin intolerance or suboptimal LDL response.
Price Variations
| Region |
Approximate Cost |
Notes |
| United States |
$5,850/year |
List price; discounts vary |
| European Union |
$4,200–$4,600/year |
Price controlled by national healthcare systems |
| Emerging Markets |
$2,500–$3,000/year |
Price reduction due to market dynamics and purchasing power |
Future Price Projections
Factors Influencing Pricing Trends
- Patent expiry: No scheduled patent expiry for evolocumab until 2029[3].
- Biosimilar development: Biosimilars are unlikely before 2028; their emergence could cut prices by 20-40%[4].
- Market penetration: Increasing use in primary prevention may sustain high prices.
- Pricing negotiations: Payer pressure could reduce effective prices by 10-15% annually.
Projected Price Range (2024–2028)
| Year |
Estimated List Price |
Effective Price (after discounts) |
Impact of Biosimilars |
| 2024 |
$6,000 |
$3,600–$4,200 |
No biosimilar impact yet |
| 2025 |
$6,150 |
$3,600–$4,150 |
Biosimilar patents pending |
| 2026 |
$6,300 |
$3,600–$4,150 |
Biosimilar market entry possible |
| 2027 |
$6,450 |
$3,700–$4,250 |
Biosimilar competition increases |
Long-term Outlook (2028–2030)
- List prices may plateau or decline by 10–15%, driven by biosimilar competition.
- Geographic price adjustments will persist based on healthcare policies.
Strategic implications
- Pricing remains high but subject to downward pressure from biosimilars.
- Payers likely to negotiate deeper discounts as market competition intensifies.
- Amgen and other players may expand indications to sustain revenue growth.
Key Takeaways
- Repatha (NDC 44087-1150) holds a dominant role in the PCSK9 inhibitor market.
- Current effective annual treatment cost ranges around $3,600–$4,200.
- Market growth driven by cardiovascular disease prevalence and expanding indications.
- Patent protections extend until at least 2029; biosimilar competition may impact pricing thereafter.
- Price reductions of 10–40% could occur over the next five years due to biosimilar entry and payer negotiations.
FAQs
1. When will biosimilars for evolocumab become available?
Biosimilars are unlikely before 2028, given patent protections and FDA approval timelines.
2. How does the price of Repatha compare with Praluent?
Repatha's list price is roughly 10–15% higher than Praluent, but effective prices vary based on discounts and insurance.
3. Will insurance coverage continue to favor reimbursement for Repatha?
Yes. Reimbursement remains strong, but prior authorization standards may tighten as biosimilar options emerge.
4. How is the market expected to evolve in regions outside the US?
Prices are lower, adjusted to local healthcare policies, and biosimilar uptake is variable.
5. What is the potential impact of Inclisiran on Repatha’s market share?
Inclisiran's longer dosing interval offers an alternative, potentially reducing the market share of second-generation PCSK9 inhibitors over time.
References
[1] Grand View Research. (2022). PCSK9 Inhibitors Market Size, Share & Trends.
[2] Centers for Medicare & Medicaid Services. (2022). Drug Pricing and Reimbursement Data.
[3] FDA. (2022). Evolocumab Product Label.
[4] IQVIA. (2022). Biosimilar Market Trends and Forecasts.
